A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca · Healthy Participants
Phase 1
Not yet recruiting
152
2026-07
Industry sponsor intelligence
AstraZenecaClinical Pipeline.
Lead-sponsor view of AstraZeneca's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 35
- Recruiting
- 2
- Active
- 1
- Completed
- 28
- Results posted
- 13
- Avg enrollment
- 256
Pipeline overview
Programs by phase and activity.
Velocity
AstraZeneca trials by start year
Study start year · indexed snapshot
Development
Trials by phase
32phase labels
Early Phase 10
Phase 18
Phase 216
Phase 35
Phase 43
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Pramlintide → | 20 | 2 | 12 | 3 | 2 | 0 |
| Bivalirudin → | 1 | 0 | 0 | 0 | 1 | 0 |
| Linaclotide → | 2 | 0 | 0 | 1 | 0 | 0 |
| Semaglutide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Cotadutide → | 9 | 5 | 4 | 0 | 0 | 0 |
| Metreleptin → | 4 | 0 | 4 | 0 | 0 | 0 |
| Glucagon → | 1 | 1 | 0 | 0 | 0 | 1 |
| Exenatide → | 1 | 0 | 0 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
AstraZeneca · Type 2 Diabetes Mellitus
Phase 3
Recruiting
1,200
2026-07
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
AstraZeneca · Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Completed
54
2025-09
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
AstraZeneca · Non-alcoholic Steatohepatitis · Type 2 Diabetes Mellitus (T2DM)
Phase 1
Completed
10
2025-07
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
AstraZeneca · Type 2 Diabetes Mellitus · Chronic Kidney Diseases
Phase 2
Completed
248
2025-01
Evaluate the Safety of Linaclotide in IBS-C Patients in China
AstraZeneca · Irritable Bowel Syndrome-IBS
Not applicable
Completed
3,028
2024-05
Chinese Multiple Dose Escalation (MDE) High Dose Study
AstraZeneca · Diabetes
Phase 1
Completed
16
2023-11
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
AstraZeneca · Diabetes Mellitus, Type 2
Phase 2
Completed
834
2020-08
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus
AstraZeneca · Type 2 Diabetes
Phase 1
Completed
16
2020-07
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
AstraZeneca · Type 2 Diabetes
Phase 2
Completed
61
2019-12
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
AstraZeneca · Type 1 Diabetes Mellitus
Phase 1
Completed
34
2018-11
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
AstraZeneca · Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 3
Completed
1,722
2016-09
Showing 10 of 28 studies
Search sponsor records
All AstraZeneca studies.
This page groups studies where AstraZeneca is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
35 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07723833A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsJul 23, 2026NCT07662213A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusJul 14, 2026NCT05663515A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsJun 23, 2026NCT05364931A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisSep 3, 2025NCT05294458A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsJul 20, 2025NCT04515849A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusJan 17, 2025NCT04462900Evaluate the Safety of Linaclotide in IBS-C Patients in ChinaMay 13, 2024NCT05437848Chinese Multiple Dose Escalation (MDE) High Dose StudyNov 7, 2023NCT05668936A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsApr 5, 2023NCT05517226Pharmacokinetics of Cotadutide in Participants With Hepatic ImpairmentMar 21, 2023